Groundbreaking biomarker study paves way for future ALS therapies
NCT ID NCT03912987
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tracks biological markers (biomarkers) in people with ALS and related disorders, as well as healthy volunteers, to better understand how these diseases progress. The goal is to help design better clinical trials for future treatments. No experimental treatments are given; participants provide samples like blood, urine, and spinal fluid over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTOTEMPORAL DEMENTIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas
Kansas City, Kansas, 66160, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.